UDCA (Ursodeoxycholic Acid).

TUDCA is ursodeoxycholic acid conjugated to taurine at the C24 carboxyl, the same conjugation the liver performs on absorbed UDCA. The two circulate as members of one bile acid pool, so stacking them raises that pool rather than adding a second mechanism.

Bile acid-CoA amino acid N-acyltransferase attaches taurine to UDCA to form the taurine conjugate, which is more water soluble and better retained in the enterohepatic circulation. Taurine availability shapes the taurine-to-glycine conjugation ratio.

Glycine is the alternative amino acid for the same N-acyltransferase step, and in humans glycine conjugates usually dominate. Loading glycine shifts the conjugate profile away from the taurine form.

Bile acids and phosphatidylcholine assemble into mixed micelles, and phospholipid content is what keeps those micelles gentle on the biliary lining. The two are the natural pairing in bile itself.

Ox bile supplies mostly cholic and deoxycholic acids, which are more hydrophobic than UDCA and shift the pool composition in the opposite direction. Combining them dilutes the hydrophilic character UDCA contributes.

Mixed bile acid preparations add hydrophobic species to the same circulating pool that UDCA is added to enrich in hydrophilic acids. The two work against each other on pool hydrophobicity.

Cholecalciferol needs bile acid micelles to cross the unstirred water layer at the brush border. Bile acid availability is a direct determinant of how much is absorbed.

Retinyl esters are hydrolysed and the free retinol partitions into bile salt micelles before uptake. Bile acid supply sets the ceiling on that step.

Alpha-tocopherol is among the most bile-dependent of the fat-soluble vitamins for absorption. Micelle formation, which bile acids drive, is the limiting step.

Menaquinones are long-chain and highly lipophilic, so they depend on bile salt micelles for uptake into the enterocyte. Bile acid availability shapes vitamin K status directly.

Long-chain triglycerides are hydrolysed by pancreatic lipase and the resulting fatty acids and monoglycerides are carried in bile salt micelles. Bile acid supply is one of the determinants of how completely EPA and DHA are absorbed.

Psyllium gel binds bile acids in the small intestine and carries them into the colon rather than allowing ileal reuptake. Taken in the same serving it lowers how much UDCA re-enters the enterohepatic circulation.

Activated charcoal adsorbs bile acids along with most other organic molecules in the gut lumen. Taken together it removes UDCA before it can be absorbed.

Chitosan carries a positive charge at gastric and upper intestinal pH and binds the anionic carboxyl group of bile acids. That is the same mechanism it uses on dietary fat.

Bentonite's layered aluminosilicate surface adsorbs organic anions including bile acids. Co-dosing lowers how much reaches the ileal bile acid transporter.

Pectin raises luminal viscosity and binds bile acids, increasing their faecal loss. The effect is milder than a resin but real when doses overlap.

Calcium ions form insoluble complexes with bile acids and fatty acids in the intestinal lumen. A large calcium dose in the same serving lowers the bile acid available for reuptake.

Phytosterols displace cholesterol and other lipids from mixed micelles because they partition into the same limited micellar space. That competition shapes what else the micelle can carry.

Lecithin is a mixed phosphatidylcholine source and contributes the phospholipid half of the mixed micelle that bile acids form. It complements rather than duplicates the bile acid itself.

Vitamin D was added to ursodeoxycholic acid in adults receiving long-term bile acid therapy for impaired bile flow, and the published report describes the combination against biochemical markers of bile flow. Vitamin D is fat soluble and its absorption depends on adequate bile acid micelle formation, which gives a straightforward reason for the pairing beyond any signalling role. The stored partner list already carries vitamin D3 as a separate entry; this row is the one with a study behind it.

Gut bacteria deconjugate bile acids with bile salt hydrolase and then 7-dehydroxylate them, which is what determines how much of an oral bile acid survives as ursodeoxycholic acid and how much becomes secondary species. A randomised trial gave ursodeoxycholic acid with probiotics in adults with high blood sugar already on a glucose-lowering medicine and reported metabolic markers. The mechanism is established microbiology; the clinical combination is a single trial and the endpoints were markers.

Yeast probiotics survive bile exposure and shift the composition of the resident bacterial community that performs bile salt deconjugation. That indirectly changes the ratio of conjugated to unconjugated bile acids reaching the colon. The reasoning is microbiological; nothing has measured this yeast with ursodeoxycholic acid.

Silymarin and ursodeoxycholic acid are combined in products marketed for normal liver function, one as a flavonolignan antioxidant and the other as a hydrophilic bile acid. The two act by unrelated mechanisms, so the pairing is additive by design rather than by a shared target. No controlled combination data supports the pairing as such.

Caffeoylquinic acids from artichoke leaf, cynarin in particular, increase bile output, while ursodeoxycholic acid changes the composition of that bile toward a more hydrophilic acid pool. Volume and composition are separate levers on the same system. The combination has not been measured, so this is mechanistic pairing.

Dandelion root has a long record of use as a bitter that stimulates bile flow, which is the same physiological direction ursodeoxycholic acid pushes when it drives bicarbonate-rich choleresis. The two arrive at the endpoint by unrelated chemistry. The pairing is traditional and formulation-driven, not tested.

Biliary phosphatidylcholine is what keeps cholesterol in solution in mixed micelles alongside bile acids, and choline is its head-group precursor. Ursodeoxycholic acid changes the bile acid side of that mixture, but the phospholipid side depends on choline supply. This is settled biochemistry of bile composition and is not a claim about a supplement combination.

Betaine donates a methyl group to regenerate methionine and then S-adenosylmethionine, which the PEMT pathway uses to methylate phosphatidylethanolamine into phosphatidylcholine. That phosphatidylcholine is the phospholipid exported into bile. The link is one-carbon biochemistry rather than a measured pairing with ursodeoxycholic acid.

N-acetylcysteine supplies cysteine for glutathione, and glutathione conjugation is one of the routes by which the liver exports compounds into bile through MRP2. Ursodeoxycholic acid acts on the bile acid pool rather than on that conjugation route. They are complementary in a general sense; nothing has tested them together.

Berberine changes the gut bacterial community that transforms bile acids and interacts with FXR and TGR5 signalling, the same receptor systems that read bile acid composition. Ursodeoxycholic acid is itself a weak modulator of those receptors. Both touch the same signalling axis, which makes a combined effect plausible and unmeasured.

Fermentable fructans shift the colonic community toward bifidobacteria and change colonic pH, which alters how much deconjugation and 7-dehydroxylation of bile acids happens. That changes the secondary bile acid pattern returning through the enterohepatic circuit. The direction of the shift is well described for fibre generally, not for this specific combination.

A feeding study in broiler chickens reported that selenium-enriched yeast shifted gut microbiota and the bile acid metabolites those microbes generate. That is an animal result about the microbial arm of bile acid handling, the same arm ursodeoxycholic acid passes through. It is not human evidence and it says nothing about combining the two in people.